...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings
【24h】

Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings

机译：用抑制剂和相关药物成本的血友病A在成人患者中引发eMicizumab疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To report the utilization of emicizumab in a patient with severe hemophilia A with inducible inhibitors and the reduction of drug costs related to decreased on-demand recombinant factor VIIa use. Case Summary: A 65-year-old African American man with established hemophilia A with an inducible factor VIII inhibitor presented with a bleeding hematoma from the right posterior thigh. The patient was historically managed on frequent administration of recombinant factor VIIa to achieve hemostasis and was started on every 2-hour dosing during this admission. Emicizumab, a new therapy for hemophilia A, became available during this admission, and the patient discontinued recombinant factor VIIa and transitioned to weekly emicizumab injections. The patient did not require any recombinant factor VIIa during the following 12 months resulting in substantial drug cost savings. Discussion: After initiation of emicizumab therapy, the patient no longer required on-demand treatment with recombinant factor VIIa for bleeds. Through this reduction in recombinant factor VIIa, there was a large decrease in inpatient drug costs and inpatient admissions for bleeding events. Conclusion: The potential reduction in drug costs and inpatient admissions should be considered when determining if emicizumab therapy is appropriate for hemophilia A patients with inhibitors. Further research is needed to confirm that continued long-term use of emicizumab remains associated with a reduction in on-demand treatment.
机译：目的：报告用诱导型血友病患者患有诱导抑制剂的患者Emicizumab的利用率，降低与需求重组因子viia降低相关的药物成本。案例摘要：一名65岁的非洲裔美国人，含有血友病A的血友病患者，诱导因子VIII抑制剂呈现出从右后腿的出血血肿。患者在历史上管理频繁管理重组因子viia以实现止血，并在此入院期间每2小时给药开始。 Emicizumab，血友病A的新疗法在此入院期间可用，并且患者停止了重组因子viia并转变为每周Emicizumab注射。患者在下面的12个月内不需要任何重组因子viia导致大量的药物成本节省。讨论：发起Emicizumab疗法后，患者不再需要随需重组因子VIIa进行渗流进行的按需治疗。通过这种重组因子viia的减少，在病毒成本和入住事件的住院性药物成本和住院入院的情况下大幅下降。结论：在确定Emicizumab治疗是否适合血友病患者抑制剂患者时，应考虑药物成本和住院入住途径的潜在降低。需要进一步研究以确认延续的长期使用Emicizumab仍然与按需治疗减少相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号